Holen Sie sich die Stockscreener-App
149.22
4.39%
6.28
Schlusskurs vom Vortag:
$142.94
Offen:
$145.61
24-Stunden-Volumen:
18.77M
Relative Volume:
7.47
Marktkapitalisierung:
$19.79B
Einnahmen:
$1.08B
Nettoeinkommen (Verlust:
$-433.19M
KGV:
-43.88
EPS:
-3.4004
Netto-Cashflow:
$-225.09M
1W Leistung:
+13.23%
1M Leistung:
+24.51%
6M Leistung:
+44.90%
1J Leistung:
+198.26%
1-Tages-Spanne:
$144.27
$151.85
1-Wochen-Bereich:
$125.12
$151.85
52-Wochen-Spanne:
$40.35
$151.85
Guardant Health Inc Stock (GH) Company Profile
Firmenname
Guardant Health Inc
Sektor
Branche
Telefon
855-698-8887
Adresse
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, NTRA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
149.22 | 18.95B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
513.03 | 187.95B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.19 | 136.75B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
551.50 | 43.78B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.01 | 38.27B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.91 | 37.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Bestätigt | Canaccord Genuity | Buy |
| 2026-02-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-09-25 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-28 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-11-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-06 | Eingeleitet | Stephens | Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-04-28 | Fortgesetzt | BTIG Research | Buy |
| 2022-02-24 | Bestätigt | Canaccord Genuity | Buy |
| 2022-02-24 | Bestätigt | Citigroup | Buy |
| 2022-02-24 | Bestätigt | Cowen | Outperform |
| 2022-02-24 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-24 | Bestätigt | SVB Leerink | Outperform |
| 2022-02-24 | Bestätigt | Stifel | Buy |
| 2022-02-24 | Bestätigt | Wells Fargo | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-11 | Eingeleitet | Stifel | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-06-12 | Eingeleitet | BTIG Research | Buy |
| 2020-02-21 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-08-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-04-16 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-04-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Bestätigt | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-29 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Guardant Health Inc Aktie (GH) Neueste Nachrichten
Enterprise value to EBITDA forward of Guardant Health, Inc. – NASDAQ:GH - TradingView
Price to book forward of Guardant Health, Inc. – NASDAQ:GH - TradingView
Guardant Health (GH) Receives Outperform Rating and $175 Price T - GuruFocus
Why Are Guardant Health (GH) Shares Soaring Today - Yahoo Finance
GH (NASDAQ: GH) insider AmirAli Talasaz sells 260,000 shares totaling $28.1M - Stock Titan
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health, Inc. Actuals & Estimates (DUS:5GH) - TradingView
Understanding the Setup: (GH) and Scalable Risk - Stock Traders Daily
GH Reinstated by Bernstein -- Price Target Announced at $175 - GuruFocus
5GH Forecast — Price Target — Prediction for 2027 - TradingView
Bernstein upgrades Guardant Health stock rating on FDA approval impact By Investing.com - Investing.com Canada
Guardant Health, Inc. Actuals & Estimates (LS:A2N5RY) - TradingView
This Men’s Health Month, a FDA-Approved Blood Test for Colorectal Cancer Offers Men an Easier Way to Screen in Nevada - Nevada Business Magazine
Form 144 Guardant Health For: 24 June By Investing.com - Investing.com South Africa
Guardant Health stock hits 52-week high at 135.89 USD - Investing.com UK
Affiliate sells 2,000 shares via cashless exercise — Guardant Health (NASDAQ: GH) - Stock Titan
Guardant Health stock climbs as investors continue to digest screening and diagnostics catalysts - Quiver Quantitative
GH Maintained by Barclays -- Price Target Raised to $150 - GuruFocus
Guardant Health stock hits 52-week high at 135.89 USD By Investing.com - Investing.com Australia
Barclays Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $150 - Moomoo
Insider Sell Alert: Musa Tariq Sells Shares of Guardant Health I - GuruFocus
Guardant Health director Myrtle Potter sells $204,084 in stock By Investing.com - Investing.com Australia
Guardant Health director Tariq Musa sells $255,893 in stock - Investing.com UK
Guardant Health director Tariq Musa sells $255,893 in stock By Investing.com - Investing.com South Africa
Guardant Health director Myrtle Potter sells $204,084 in stock - Investing.com UK
Form 4 Guardant Health Inc For: 23 June By Investing.com - Investing.com Australia
Guardant Health (GH) director sells 1,951 shares in open-market trade - Stock Titan
Guardant Health (GH) director trims holdings with 1,556-share sale - Stock Titan
Guardant Health (GH) director exercises RSUs, acquires 528 common shares - Stock Titan
Form 144 Guardant Health For: 22 June By Investing.com - Investing.com Australia
Form 4 Guardant Health Inc For: 22 June By Investing.com - Investing.com Australia
Guardant Health (GH) director adds 4,203 shares and receives 2,711 RSUs - Stock Titan
Guardant Health (GH) director exercises 4,203 RSUs and receives 2,711-unit grant - Stock Titan
Guardant Health (GH) director Mignone exercises 4,203 RSUs and receives 2,711-unit grant - Stock Titan
Guardant Health (NASDAQ: GH) director gains shares as 4,203 RSUs vest and 2,711 new units granted - Stock Titan
Guardant Health (GH) director Meghan Joyce gains 4,203 shares from RSU vesting - Stock Titan
Guardant Health (GH) director exercises 4,435 RSUs and receives 2,711-unit award - Stock Titan
Guardant Health (GH) director reports RSU vesting, 5,092 shares and new 2,711 RSU grant - Stock Titan
Finanzdaten der Guardant Health Inc-Aktie (GH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):